Santhanam Subramanian, Chief Financial Officer (CFO) of the country’s leading pharma company Aurobindo Pharma, made a big announcement on Monday. He expressed hope that the company’s unit in China will start production in the next quarter (October-December 2024). Apart from this, the China-based plant is expected to start full-scale production in the next financial year. This Hyderabad-based pharma company plans to start small-scale production in the November-December period and hopes to increase it in the January-March quarter next year.
What did the company’s CFO say about the China plant?
Speaking to experts, Santhanam Subramanian said, “The China plant is expected to start from the third quarter of FY 2024-25 and production will increase from the fourth quarter.” He said that full production at this plant will start in FY 2025-26.
Big increase in production expected from October this year
The company’s CFO said, “We are trying to do some filings for China as well as the US. So all this will increase the revenue potential of China in the coming years. This year, we will see just a small volume and value.” He said the company is also on the right track with regard to large-scale commercialisation of Pen-G (penicillin). He said the company is expecting a major increase in production from October this year.
Pen-G plant gets approval under PLI scheme
The company’s Rs 2,400 crore Pen-G plant in Andhra Pradesh, which was approved under the Production-Linked Incentive (PLI) scheme to promote local manufacturing of critical key starting materials (KSMs)/drug intermediates and active pharmaceutical ingredients (APIs) in the country, will have an annual production capacity of around 15,000 tonnes.
Latest Business News
